TLDR
- Pfizer hit a new 52-week high of $29.09 on Tuesday, last trading at $28.75
- Q2 2026 earnings beat estimates: EPS of $0.77 vs $0.68 expected, revenue of $15.03B vs $14.42B expected
- Pfizer raised its full-year 2026 revenue outlook following the earnings beat
- The company settled over 6,000 federal Depo-Provera lawsuits, removing a major legal overhang
- Consensus analyst rating remains “Hold” with an average price target of $28.28
Pfizer hit a new 52-week high of $29.09 on Tuesday, with the stock last trading at $28.75. That puts the stock up roughly 20% year-to-date, a strong run for a company that has spent the better part of two years navigating the post-COVID revenue hangover.
Volume on the day came in at over 8.3 million, above typical levels, suggesting renewed investor interest.
The move comes on the back of a solid Q2 2026 earnings report. Pfizer posted adjusted EPS of $0.77, beating the Wall Street consensus of $0.68 by $0.09. Revenue hit $15.03 billion, topping expectations of $14.42 billion.
Revenue was up 2.6% compared to the same quarter last year. It’s not explosive growth, but it’s growth, and the market has noticed.
Following the beat, Pfizer raised its full-year 2026 EPS guidance to a range of $2.80 to $3.00. Analysts currently expect the company to land at $2.98 for the full year.
Erste Group Bank also lifted its fiscal 2026 EPS estimate for Pfizer after the results, adding to the positive momentum around the print.
Depo-Provera Settlement Clears the Deck
One of the bigger story lines this week is the resolution of the Depo-Provera litigation. Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits tied to claims that the contraceptive was linked to intracranial meningioma.
Financial terms were not disclosed and Pfizer admitted no liability. But getting that legal cloud off the books matters. Investors had been watching that case closely, and its resolution removes a real source of uncertainty.
Oncology Pipeline in Focus
Pfizer’s oncology business continues to get attention from analysts. Padcev is currently the growth leader in that segment, and the company has additional pipeline programs including PF-08634404 that could support longer-term revenue.
Label expansions in oncology are also being tracked as a potential offset to pressure in other parts of the business as older products face generic competition.
On the dividend front, Pfizer paid out $0.43 per quarter on September 1st to shareholders of record as of July 24th. That works out to a $1.72 annualized dividend and a yield of around 6%.
That yield has made PFE a talking point among investors rotating toward income-generating names as tech and AI valuations stay elevated.
Analyst sentiment is mixed. Royal Bank of Canada upgraded the stock from underperform to sector perform in June, while HSBC cut it from buy to hold in July and trimmed its target from $32 to $28. Cantor Fitzgerald holds a neutral rating with a $27 target, and Wolfe Research keeps an underperform with a $26 target.
The overall consensus sits at “Hold” with an average price target of $28.28, just below where the stock is currently trading.
Institutional investors own 68.36% of Pfizer. Several smaller funds added new positions in the first and second quarters of 2026.
The stock’s 50-day moving average stands at $25.62 and its 200-day at $26.30, both now well below the current price.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
